The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population

Abstract Background Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (...

Full description

Bibliographic Details
Main Authors: Massimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, Elisabetta Abruzzese, Gianni Binotto, Luigi Scaffidi, Maddalena Cordioli, Daniela Damiani, Eros Di Bona, Malgorzata Monika Trawinska, Ilaria Tanasi, Maria Vittoria Dubbini, Vanessa Velotta, Giulia Ceccarelli, Elisabetta Pierdomenico, Mariella Lo Schirico, Gianpietro Semenzato, Marco Ruggeri, Renato Fanin, Evelina Tacconelli, Giovanni Pizzolo, Mauro Krampera
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Cancer Medicine
Subjects:
chronic myeloid leukemia
COVID‐19
prevalence
serological tests
TKIs
Online Access:https://doi.org/10.1002/cam4.4179

Internet

https://doi.org/10.1002/cam4.4179

Similar Items